Litigation Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-01-27 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 10,543,179; 9,187,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-04-06 | 234 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 10,543,179 ("the '179 patent"). The '179 patent relates to…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which…quot;A claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…that inform patent law." Id. The ultimate question of the proper construction of a patent is a question…x27;s construction of U.S. Patent No. 9,187,405 ("the '405 patent") in Novartis Pharmaceuticals | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
